Join to View Full Profile
9500 Euclid AveCleveland, OH 44195
Phone+1 216-445-7238
Dr. Valent is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jason Valent is an oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in amyloidosis and multiple myeloma.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2002 - 2006
University of Cincinnati College of MedicineClass of 2002
Certifications & Licensure
OH State Medical License 2002 - 2027
MI State Medical License 2006 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Start of enrollment: 2016 Mar 01
Publications & Presentations
PubMed
- Current management of non-amyloidosis monoclonal gammopathy of renal significance: Clinical features, treatment selections, responses and renal outcomes.Daniel Cancilla, Hanny Sawaf, Xuefei Jia, Danai Dima, Ali Mehdi
British Journal of Haematology. 2025-10-23 - Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.Ali Mushtaq, Asfand Yar Cheema, Hossam M Ali, Yara Shatnawi, Omer Ashruf
Blood Reviews. 2025-09-27 - Molecular Expression Differences in Specific Blood Mononuclear Cell-Types Identify Patients With AL Amyloidosis.David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Sandra Mazzoni
Journal of Cellular and Molecular Medicine. 2025-09-01
Abstracts/Posters
- Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple MyelomaJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) PatientsJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Rapid Infusion Daratumumab Is Safe in Patients with AL AmyloidosisJason Valent, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Ref...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- ASH 2020 Study Preview: Dose Escalation of Cael-101 in AL Amyloidosis PatientsDecember 2020
Press Mentions
Amyloidosis Patient Credits Faith and Family for SurvivalSeptember 30th, 2025- Top Myths About CAR T-cell Therapy for Multiple MyelomaFebruary 18th, 2025
- Reader Responses: Should a Mostly Asymptomatic Patient with Amyloidosis Receive Systemic Therapy?May 1st, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
